Annonce • Jun 09
Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026 Addex Therapeutics Ltd, Annual General Meeting, Jun 29, 2026, at 11:00 W. Europe Standard Time. Location: at the campus biotech, chemin des mines 9,1202., geneva Switzerland Annonce • May 02
Addex Therapeutics Ltd announced delayed 20-F filing On 04/30/2026, Addex Therapeutics Ltd announced that they will be unable to file their next 20-F by the deadline required by the SEC. Annonce • May 01
Addex Therapeutics Demonstrates Solid Anti-Tussive Activity of GABAB PAM Candidate in Bleomycin IPF-Related Chronic Cough Model Addex Therapeutics announced encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model. In studies evaluating chronic once-daily (QD) administration of a lead GABAB PAM candidate in BLM-exposed animals, robust and sustained antitussive efficacy was observed, with significant reductions in cough frequency and increased cough latency over the treatment period. Improved lung pathology outcomes, including lower Ashcroft scores and reduced percentage of affected lung tissue suggesting an impact on fibrosis, were demonstrated compared to untreated BLM-exposed animals at both Day 7 and Day 28. The safety profile remained favorable, with no meaningful changes in respiratory rate, or body temperature. The compound was well tolerated throughout the study, supporting its potential for chronic administration. The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed throughout the central and peripheral cough neural circuit as well as in the lungs and airways. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects including sedation, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound. Annonce • Apr 22
Addex Therapeutics Ltd Demonstrates Robust Anti-Tussive Activity of Gabab Pam Candidate in Non-Human Primate Chronic Cough Model Addex Therapeutics Ltd. announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. In the NHP model of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency. In the same model, the antitussive efficacy of the GABAB PAM drug candidate was similar to that observed with baclofen. As previously reported, in the citric acid induced guinea pig model of chronic cough, the GABAB PAM drug candidate significantly reduced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the GABAB PAM drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuphine, baclofen, or codeine, while being similar to that of a P2X3 inhibitor, based on the compound’s activity on respiratory rate. Annonce • Mar 09
Addex Therapeutics Ltd to Report Fiscal Year 2025 Final Results on Apr 27, 2026 Addex Therapeutics Ltd announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 27, 2026 Annonce • Jan 07
Addex Spin-Out Neurosterix Starts A Phase 1 Clinical Study with M4 Pam - Ntx-253 for Schizophrenia Addex Therapeutics Ltd. announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. The progression of NTX-253 into clinical studies represents an important milestone for both Neurosterix and Addex. The M4 muscarinic receptor is a validated target for treating schizophrenia and related disorders through indirect modulation of dopamine signaling. NTX-253 is an potent, selective, orally available PAM of M4 that fine-tunes muscarinic signaling with the potential to reduce psychosis symptoms while avoiding the movement disorders and metabolic complications associated with traditional dopamine antagonists. Preclinical studies demonstrate robust antipsychotic-like activity and a favorable safety profile, supporting advancement into first-in-human clinical studies. Currently available antipsychotics typically target dopamine receptors, providing some success in ameliorating the positive symptoms of the disorder. However, targeting dopamine also can induce metabolic, cognitive, and motor side effects, limiting their therapeutic utility. Research suggest that M4 PAMs could indirectly modulate dopamine levels and induce antipsychotic activity without peripheral muscarinic side- effects seen with direct agonists. Highly selective M4 PAMs have been found to have robust antipsychotic-like effects in multiple rodent models and reverse multiple in vivo effects of psychomotorstimulants that induce increases in extracellular dopamine. Annonce • Jun 18
Addex Therapeutics Ltd to Report Q1, 2025 Results on Jun 19, 2025 Addex Therapeutics Ltd announced that they will report Q1, 2025 results on Jun 19, 2025 Annonce • Jun 06
Addex Therapeutics Announces Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models Addex Therapeutics announced robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs. Some of these preclinical data with Addex GABAB PAM drug candidate will be presented on June 7, 2025 at the 10thAmerican Cough Conference, in Dulles, Virginia by Dr. Mikhail Kalinichev, Head of Translational Science at Addex. In models of chronic cough, the GABAB PAM drug candidate significantly reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In the same model, the antitussive efficacy of the Addex GABAB PAM Drug candidate appears to be superior to that observed with nalbuphine, baclofen, codeine or a P2X3 inhibitor. In addition, the tolerability of the GABAB PAM candidate demonstrated better tolerability and a wider therapeutic margin than that observed with nalbuPHine, baclofen), or codeine, while being similar to that of a P2X3 inhibitor, based on the compound's activity on respiratory rate. About GABAB activation and cough: The main inhibitory neurotransmitter GABA activates ionotropic (GABAA) and metabotropic (GABAB) types of receptors. GABAB receptors are widely expressed on airways and in the central and peripheral components of the cough neural circuit. Activating GABAB receptors to treat chronic cough has been clinically validated with baclofen, a selective GABAB agonist, that binds the receptor within the GABA binding, orthosteric site. Baclofen is used off-label to treat chronic cough patients, but its wider use is limited due to serious side effects, short half-life and gradual loss of efficacy during chronic treatment. Targeting an allosteric site of the receptor encompasses many advantages, including higher selectivity, better tolerability and lack of tolerance compared to an orthosteric compound. Annonce • Jun 04
Addex Therapeutics Ltd, Annual General Meeting, Jun 24, 2025 Addex Therapeutics Ltd, Annual General Meeting, Jun 24, 2025, at 11:00 W. Europe Standard Time. Location: campus biotech, chemin des mines 9, 1202, geneva Switzerland Annonce • May 01
Addex Therapeutics Ltd announced delayed 20-F filing On 04/30/2025, Addex Therapeutics Ltd announced that they will be unable to file their next 20-F by the deadline required by the SEC. Annonce • Apr 24
Addex Therapeutics Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Addex Therapeutics Ltd announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Apr 25, 2025 Annonce • Apr 17
Addex Regains Rights to Phase 2 Mglu2 Pam Asset ADX71149 Addex Therapeutics announced that following the previously announced termination of development of ADX71149 (JNJ-40411813) in epilepsy, its partner Janssen Pharmaceuticals Inc. (now known as J&J Innovative Medicine) has return all development and commercialization rights to ADX71149 (JNJ-40411813) and the partnership between the two companies has been terminated. Annonce • Sep 10
Addex Therapeutics Ltd to Report First Half, 2024 Results on Sep 16, 2024 Addex Therapeutics Ltd announced that they will report first half, 2024 results on Sep 16, 2024 Annonce • Aug 27
Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration Addex Therapeutics Ltd. and Indivior PLC announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration. Indivior has selected a compound for future development in substance use disorder and will now undertake all future development of their selected compound. Under the terms of the agreement, Addex is eligible for payment of up to USD 330 million on successful achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single digits up to low double-digit. Under the terms of the Agreement, Addex has also exercised its right to select a compound to advance its own independent GABAB PAM program for the treatment of chronic cough. The selection of GABAB PAM clinical candidates is the culmination of more than five years of research at Addex in close collaboration with the team at Indivior. During this time, the company were able to pinpoint specific candidates from thousands of compounds using the power of industrial-scale allosteric modulator discovery platform. The selection of GAM clinical candidates is the culmination the culmination of more than five year of research at Addex in near collaboration with the team at IndIVior. During this time, company were able to pinpoint specific candidate from thousands of compounds using the Power of industrial-scale allosterIC modulator discovery platform. The company look forward to the next steps in the development of the substance use disorder program under the control of Indivior. On the Addex side, the company are now focused on advancing its selected clinical candidate for chronic cough into IND enabling studies. Activation of gamma-aminobutyric acid subtype BGABAB) receptor, a Family C class of GPCR, is clinically and commercially validated. The generic GABAB receptor agonist, baclofen, marketed for spasticity, has been shown to be efficacious in several other disease areas, including alcohol use disorder, CMT1A, overactive bladder, chronic cough and pain. However, its wider use is limited due to a variety of side effects, rapid clearance and the development of tolerance. novel, potent, selective and orally available PAMs that potentiate GABA responses, rather than acting as orthosteric agonists at the GABAB receptor, like baclofen, are expected to deliver efficacy and have fewer adverse effects. Furthermore, PAMs only act when the natural ligand (GABA) activates the natural ligand (GAB) receptor. Annonce • Jul 15
Addex Therapeutics Ltd Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium Addex Therapeutics Ltd. announced that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13 LICS) on July 19 and an abstract is available to conference participants on-line from July 15, 2024. In models of chronic cough in guinea pigs, the candidate GABAB PAM, significantly and dose-dependently reduced citric acid-induced cough frequency (minimal efficacious dose 1 mg/kg), increased cough latency and showed no signs of tolerance after sub-chronic treatment. In comparison with the GABAB agonist baclofen, the selective GABAB PAM showed a wider safety margin, separating its minimal efficacious dose from the dose linked to side-effects. Baclofen exhibits antitussive properties, but its broad clinical use is hampered by its short half-life and central nervous system side effects including sedation. Annonce • Jun 08
Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024 Addex Therapeutics Ltd, Annual General Meeting, Jun 28, 2024, at 11:00 W. Europe Standard Time. Location: geneva Switzerland Annonce • Apr 11
Addex Therapeutics Ltd to Report Fiscal Year 2023 Results on Apr 18, 2024 Addex Therapeutics Ltd announced that they will report fiscal year 2023 results at 12:00 PM, Central European Standard Time on Apr 18, 2024 Annonce • Apr 05
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders Addex Therapeutics announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders. With initial funding of $63 million from Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures, Neurosterix will acquire a portfolio of preclinical assets and the allosteric modulator drug discovery technology platform from Addex and accelerate their development. Addex's pipeline now consists of: ADX71149 - a metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) currently in a Phase 2 clinical study for the treatment of epilepsy in collaboration with Janssen Pharmaceuticals Inc.; A GABAB PAM program licensed to Indivior currently in clinical candidate selection with a focus on substance use disorder; Dipraglurant a Phase 2 ready mGlu5 NAM under evaluation for future development in dyskinesia associated with Parkinson's disease and post-stroke/traumatic brain injury (TBI) recovery; and GABAB PAMs in clinical candidate selection for chronic cough. The launch of Neurosterix in partnership with Perceptive is an important validation of the Addex allosteric modulator drug discovery technology platform and provides the resources to accelerate development of important preclinical assets, including the M4 PAM and mGlu7 negative allosteric modulator (NAM) programs, into the clinic This transaction significantly reduces Addex operating costs and provides CHF5 million of cash thereby extending cash runway beyond 2026. This allows to reach important milestones from partnered programs, including the Phase 2 epilepsy data from Janssen partnership in the second quarter of 2024 as well as retaining an important upside in the future of Neurosterix through 20% equity interest. Allosteric modulators bind to their target receptor outside of the active site, where the natural ligand and traditional drugs operate. This non-competitive mode of action brings greater selectivity and more precision over the control of biological pathways, potentially delivering improved efficacy and safety. Addex pioneered the development of high-throughput industrial-scale discovery tools for allosteric modulator drug discovery, which have delivered a broad pipeline of oral small molecule drug candidates with the potential to transform the treatment of multiple neurological disorders. Addex's pipeline now consists of: ADX71149 - a metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) currently in a Phase 2 clinical study for the treatment of epilepsy in collaboration with Janssen Pharmaceuticals Inc.; A GABAB PAM program licensed to Indivior currently in clinical candidate selection with a focus on substance use disorder; Dipraglurant a Phase 2 ready mGlu5 NAM under evaluation for future development in dyskinesia associated with Parkinson's disease and post-stroke/traumatic brain injury (TBI) recovery; and GABAB PAMs in clinical candidate selection for chronic cough. Annonce • Jan 31
Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million. Addex Therapeutics Ltd has filed a Follow-on Equity Offering in the amount of $2.15 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Transaction Features: At the Market Offering Annonce • Nov 15
Addex Therapeutics' ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients Addex Therapeutics announced that the last patient has been randomized in Cohort 2 of the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study. Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024. The primary efficacy endpoint of this study is time to baseline monthly seizure count. The trial is being conducted in collaboration with Janssen Pharmaceuticals Inc., a Johnson & Johnson company. ADX71149 is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM). The multi-center Phase 2 study has been designed to assess the efficacy, safety, tolerability, and pharmacokinetics of adjunctive ADX71149 administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The primary objective of the study is to evaluate the efficacy of ADX71149 in combination with levetiracetam or brivaracetam using a time to baseline seizure count endpoint. Part 1 of the study evaluates the acute efficacy of ADX71149 over 4 weeks. Patients who do not reach their monthly baseline seizure count in Part 1 continue double-blind treatment during Part 2 until they reach their monthly baseline seizure count or 8 weeks, deemed the maintenance efficacy phase. In addition, patients who complete Part 1 and/or Part 2 of the study have the option to continue treatment in the open-label extension part of the study, which evaluates the long-term efficacy and safety of ADX71149. More information on the study can be found with Clinicaltrials.gov identifier NCT04836559. Annonce • Nov 08
Addex Regains Nasdaq Listing Compliance Addex Therapeutics announced it had received written notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. Addex announced on May 18, 2023 that it had been notified by Nasdaq that its ADSs were not in compliance with the minimum bid price rule. To regain compliance, Addex was required to maintain a minimum closing bid price of $1.00 per ADS for at least 10 consecutive business days. This requirement was met on November 3, 2023. Annonce • Sep 05
Addex Therapeutics Announces Data Published in Brain Addex erapeutics announced that data published in Brain demonstrating the potential therapeutic role of mGlu5 receptor negative allosteric modulators (NAMs) in facilitating functional recovery following stroke supports the future development of dipraglurant in post-stroke recovery. Dipraglurant is a novel, orally available, highly selective mGlu5 NAM ready for Phase 2 clinical studies, currently being evaluated in preclinical models of post-stroke recovery. Functional recovery following stroke relies on the formation of new or reactivation of existing neural connections while accumulating evidence suggests that the mGlu5 receptor modulates brain plasticity and function. The researchers investigated the influence of mGlu5 inhibition on this network reorganization and functional recovery in preclinical models of stroke. In the publication, titled "Inhibiting metabotropic glutamate receptor 5 after stroke restores brain function and connectivity", the data showed that daily treatment with mGlu5 NAMs for 12 days, starting 2 or 10 days after stroke, restored lost somatosensory functions without diminishing infarct size. Within hours of treatment, somatosensory recovery expressed in normalized use of affected limbs, was apparent and progressed for the subsequent 12 days. There is a huge unmet medical need for novel treatments to help stroke patients recover, and there are currently no approved drugs that promote functional recovery. Annonce • Aug 04
Addex Therapeutics Ltd announced that it has received CHF 2.7 million in funding from Indivior PLC Addex Therapeutics Ltd announced that it has received CHF 2,700,000 in a round of funding on August 3, 2023. The transaction included participation from returning investor Indivior PLC. Annonce • Jul 25
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder Addex Therapeutics announced data showing that administration of a metabotropic glutamate 2 (mGlu2) positive allosteric modulator significantly reduces oxycodone self-administration in preclinical models, supporting a potential role in opioid use disorder. The data were published in Neuropharmacology by Addex and The Scripps Research Institute. The aim of the study was to test whether the mGlu2 receptor positive allosteric modulator ADX106772 could reduce oxycodone self-administration and the conditioned reinstatement of oxycodone seeking without affecting behaviors directed toward a highly palatable non-drug reinforcer (sweetened condensed milk, SCM). Rats were trained to self-administer oxycodone (0.15 mg/kg/infusion, i.v.,12 h/day) or sweetened condensed milk for 13 days in the presence of a contextual/discriminative stimulus (SD). Oxycodone, SCM, and the SD were then withheld. Once oxycodone or SCM self-administration was acquired and oxycodone dependence verified, the effect of ADX106772 (0.3, 1, 3, or 10 mg/kg, s.c.) was tested on oxycodone or SCM self-administration. ADX106772 was found to reduce oxycodone self-administration and conditioned reinstatement without affecting SCM self-administration or conditioned reinstatement. ADX106772 reduced oxycodone taking and seeking but did not affect the motivation for the palatable conventional reinforcer. Annonce • May 19
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency On May 18, 2023, Addex Therapeutics Ltd. announced that it had received written notification from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Company’s American Depositary Shares (ADSs) had closed below the minimum USD 1.00 per ADS requirement for continued listing on Nasdaq under listing rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Addex has been provided an initial period of 180 calendar days to regain compliance and will receive written notification if the Company achieves compliance at any time during this period. Compliance will be achieved if the bid price of the ADSs closes at USD 1.00 per ADS or more for a minimum of ten consecutive business days. Addex will monitor the bid price of its ADSs and evaluate options to regain compliance with Nasdaq’s minimum bid price rule within the compliance period. If compliance with Rule 5550(a)(2) is not regained by November 8, 2023, the Company may be eligible for an additional 180 calendar day compliance period. Addex’s operations are not affected by the receipt of the notification letter and The Company fully intends to resolve the deficiency and regain compliance with the Nasdaq Listing Rules. Annonce • May 11
Addex Therapeutics Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Addex Therapeutics announced that the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study has been recommended to continue by an Independent Interim Review Committee (IRC) following review of unblinded data from Part 1 of patient Cohort 1. The clinical study is being conducted by Janssen Pharmaceuticals Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. ADX71149 is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM). The multi-center Phase 2 study has been designed to assess the efficacy, safety, tolerability, and pharmacokinetics of adjunctive ADX71149 administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. Up to 3 doses (low, medium, high) of ADX71149 in up to 160 patients will be evaluated. The primary objective of the study is to evaluate the efficacy of ADX71149 in combination with levetiracetam or brivaracetam using a time to baseline seizure count endpoint. Part 1 of the study evaluates the acute efficacy of ADX71149 over 4 weeks. Subjects who do not reach or exceed their monthly baseline seizure count in Part 1 continue double-blind treatment during Part 2 until they reach their monthly baseline seizure count or 8 weeks, deemed the maintenance efficacy phase. Cohort 1 has completed Part 1 and is currently in Part 2. Cohort 2 has started to recruit patients in Part 1. In addition, patients who complete Part 1 and/or Part 2 of the study have the option to continue treatment in the open-label extension part of the study, which evaluates the long-term efficacy and safety of ADX71149 for up to 2 years. More information on the study can be found with Clinicaltrials.gov identifier NCT04836559. Glutamate mGlu2 Receptors and Epilepsy, Glutamate is the primary excitatory neurotransmitter in the brain and plays a key role in the initiation and spread of seizures. When activated, the mGlu2 receptor decreases the release of glutamate and consequently, helps to maintain neurotransmitter balance. In the presence of agonist-induced activation, positive allosteric modulation of mGlu2 receptors could result in the normalization of the excessive glutamate release seen during a seizure. There is still an urgent need for more effective treatments for epilepsy, with improved tolerability and safety. ADX71149 was described in the Eilat 15 conference summary review as a promising novel approach currently in development (Bialer et al., 2020. Epilepsia). Proof of concept data with ADX71149 and other mGlu2 PAMs in animal models of epilepsy have been published in peer-reviewed journals (Metcalf et al., 2017 and 2018. Epilepsia). Annonce • Feb 10
Addex Regains Nasdaq Listing Compliance Addex Therapeutics announced notification from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement of $1.00 per ADS share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing. Addex announced on November 3, 2022 that it had been notified by Nasdaq that its ADSs were not in compliance with the minimum bid price rule. To regain compliance, Addex was required to maintain a minimum closing bid price of $1.00 for at least 10 consecutive business days. This requirement was met on February 7, 2023. 
